NovaBay receives $2.6M to advance Aganocide research

NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.